Dare Bioscience, Inc.
DARE · XNASCIK 1401914fmd_07P4T13QTC4S707PQJXMB7HQFE制造业 · 医药制剂模板: 标准
覆盖范围: 2012年1月01日 至 2026年6月30日，共 55 个期间
| 项目 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| 营业总收入 | 1 | – | – | – | – | 0 | 10 | 3 | 0 | 1 |
| 营业成本 | – | – | – | – | – | – | – | – | 0 | 0 |
| 毛利润 | – | – | – | – | – | – | – | – | 0 | 1 |
| 研发费用 | 0 | 1 | 6 | 9 | 21 | 31 | 30 | 22 | 14 | 6 |
| 销售、一般及管理费用 | – | – | – | – | – | – | – | – | 9 | 9 |
| 营业费用合计 | 1 | 11 | 17 | 14 | 27 | 39 | 41 | 34 | 23 | 14 |
| 营业利润 | (1) | (11) | (17) | (14) | (27) | (39) | (31) | (31) | (23) | (14) |
| 利息费用 | 0 | 0 | – | – | – | – | – | – | – | – |
| 利息及投资收益 | 0 | – | – | – | – | – | – | – | – | – |
| 其他营业外收入（支出） | (2) | (0) | 0 | 0 | 0 | 0 | 0 | 1 | 1 | (0) |
| 税前利润 | (1) | (12) | (17) | (14) | (27) | (39) | (31) | (30) | (4) | (14) |
| 所得税费用 | – | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 持续经营净利润 | – | (12) | (17) | (14) | (27) | (39) | (31) | (30) | (4) | (14) |
| 净利润 | (1) | (12) | (17) | (14) | (27) | (39) | (31) | (30) | (4) | (13) |
| 归属于普通股股东的净利润 | (39) | – | (17) | (15) | (27) | (39) | (31) | (30) | (4) | (13) |